C. Messina

发表

Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.

V. Conteduca, V. Zagonel, F. Massari, 2015, Future oncology.

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.

C. Sternberg, F. Atzori, M. Milella, 2013, European journal of cancer.

Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.

P. Marchetti, F. Boccardo, G. Di Lorenzo, 2014, Future oncology.

Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

V. Conteduca, F. Massari, U. de Giorgi, 2015, BJU international.

Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer

G. Sonpavde, V. Zagonel, G. Di Lorenzo, 2016, Medicine.

Prevalence and Clinical Impact of SARS‐CoV‐2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID‐19 Pandemic

M. Mandalà, S. Mosconi, A. Zambelli, 2020, The Oncologist.

Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.

V. Conteduca, F. Massari, U. de Giorgi, 2018, Future oncology.

Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC).

L. Mariani, C. Morosi, N. Zaffaroni, 2011, Journal of Clinical Oncology.

Targeting androgen-independent pathways: new chances for patients with prostate cancer?

A. D. Meglio, A. Di Meglio, F. Boccardo, 2017, Critical reviews in oncology/hematology.

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.

V. Conteduca, V. Zagonel, F. Massari, 2015, European urology.

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.

V. Zagonel, G. Di Lorenzo, F. Massari, 2016, Future oncology.

Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.

G. Di Lorenzo, F. Massari, U. de Giorgi, 2015, Urologic oncology.

Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.

Alessio Farcomeni, Valentina Baldazzi, Giuseppe Procopio, 2015, The Journal of urology.

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

L. Schwartz, L. Mariani, F. D. De Braud, 2012, The Lancet. Oncology.

The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone.

J. Radford, M. Gospodarowicz, G. Martinelli, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy

L. Schwartz, L. Mariani, F. D. De Braud, 2013, British Journal of Cancer.

Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.

C. Porta, V. Zagonel, M. Aglietta, 2021, European Journal of Cancer.

Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.

V. Conteduca, V. Zagonel, F. Massari, 2016, Clinical genitourinary cancer.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study

S. Barni, V. Adamo, M. Bruno, 2016, Oncotarget.

Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment.

C. Sternberg, F. Calabrò, L. Cerbone, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial

C. Porta, G. Procopio, E. Verzoni, 2020, Tumori.

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer

R. Labianca, C. Porta, A. Vaglio, 2010, Cancer Immunology, Immunotherapy.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).

F. Atzori, L. Cerbone, F. Boccardo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.

C. Sternberg, F. Atzori, M. Milella, 2013, European journal of cancer.

Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.

G. Di Lorenzo, F. Massari, U. de Giorgi, 2015, Urologic oncology.